INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 188 filers reported holding INOVIO PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.85 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1 | -66.7% | 1,727 | +5.3% | 0.00% | – |
| Q4 2022 | $3 | -99.9% | 1,640 | 0.0% | 0.00% | – |
| Q3 2022 | $4,000 | +33.3% | 1,640 | 0.0% | 0.00% | – |
| Q2 2022 | $3,000 | -50.0% | 1,640 | 0.0% | 0.00% | – |
| Q1 2022 | $6,000 | -80.6% | 1,640 | -78.2% | 0.00% | – |
| Q4 2021 | $31,000 | -70.5% | 7,520 | -48.6% | 0.00% | -100.0% |
| Q3 2021 | $105,000 | -22.8% | 14,640 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $136,000 | +580.0% | 14,640 | +584.1% | 0.00% | – |
| Q1 2021 | $20,000 | -68.3% | 2,140 | -70.1% | 0.00% | – |
| Q4 2020 | $63,000 | -47.1% | 7,165 | -29.9% | 0.00% | -100.0% |
| Q3 2020 | $119,000 | -69.7% | 10,221 | -29.9% | 0.00% | -75.0% |
| Q2 2020 | $393,000 | +4812.5% | 14,573 | +1189.6% | 0.00% | – |
| Q1 2020 | $8,000 | -91.4% | 1,130 | -92.3% | 0.00% | -100.0% |
| Q3 2017 | $93,000 | – | 14,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |